Omega-3 Fatty Acids

This page as PDF · Summary

1. What Omega-3 Fatty Acids Are

Omega-3 fatty acids are polyunsaturated fatty acids with a double bond at the third carbon atom. The most important representatives include eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), which are primarily found in oily fish, algae, and some plant oils. Alpha-linolenic acid (ALA) is a plant-based precursor that the body can convert to EPA and DHA to a limited extent. Biological activity strongly depends on the chemical structure: in natural sources, EPA and DHA are mostly present as triglycerides or phospholipids, whereas synthetic preparations often contain ethyl esters.

For research, bioavailability is a central challenge. Studies show that the absorption of omega-3 fatty acids varies depending on formulation (triglycerides vs. ethyl esters) and co-administered substances (e.g., dietary fat). Additionally, effects are often measured using the omega-3 index—the proportion of EPA and DHA in erythrocyte membranes. However, this marker does not always correlate with clinical endpoints. The diversity of sources studied (fish oil, krill oil, algae oil) and dosages complicates direct comparisons between studies.

2. What the Studies Show in Detail

Key human studies and major reviews — by application area, including population, duration, preparation, measured parameters, and results, as reported in the original publications. Numbers are included only where the study provides them.

Distribution of controlled human studies by application area — numbers are not additive, as one study may be assigned to multiple areas:

Oncology

Women aged ≥55 years were treated for a median of 5.3 years with 1 g/day of marine omega-3 fatty acids (EPA/DHA) or placebo. Primary endpoints were major cardiovascular events (myocardial infarction, stroke, or cardiovascular death) and invasive cancers of any type. The study showed no significant difference between the verum and placebo groups regarding the incidence of cancers (hazard ratio not explicitly stated in the abstract but described as non-significant). Secondary endpoints, such as specific cancer types or cancer-related deaths, also showed no significant effects. A limitation is that the study was primarily designed for cardiovascular prevention, with cancer incidence investigated as a secondary endpoint. Additionally, the focus was on a population with average risk, which limits generalisability to high-risk groups. 1

There is a lack of targeted oncological studies on omega-3 fatty acids that examine specific cancer entities, higher dosages, or longer observation periods.

Skin and Autoimmune Diseases

The primary endpoint in this controlled human study was the incidence of confirmed autoimmune diseases (including rheumatoid arthritis, psoriasis, and autoimmune thyroid diseases). No significant effects were observed for individual diseases such as psoriasis or rheumatoid arthritis. A limitation is the short follow-up period of 5.3 years, which may be insufficient to capture long-term effects on autoimmune disease development. Additionally, diagnoses were based on self-reports validated by medical records, which could lead to underreporting of milder cases. 2

Hypothesis The observed trend towards a reduced incidence of autoimmune diseases may be attributable to the anti-inflammatory effects of omega-3 fatty acids, which may be particularly effective in subclinical inflammatory processes.

Cognition and Mental Health

Primary endpoints included cognitive performance (e.g., executive functions), structural neuroimaging (white matter microstructure, grey matter volumes), and vascular markers (carotid intima-media thickness, diastolic blood pressure). The study demonstrated an improvement in executive functions in the omega-3 group compared to placebo (p = 0.023). In parallel, white matter microstructure and grey matter volumes improved in frontal, temporal, parietal, and limbic regions (primarily left-hemispheric). Additionally, carotid intima-media thickness and diastolic blood pressure decreased. Improvements in executive functions correlated positively with increases in the omega-3 index and peripheral brain-derived neurotrophic factor (BDNF) and negatively with increases in fasting insulin. 3

Some studies varied widely in dosage (e.g., 1 g/day to 2.2 g/day), duration (8 weeks to 26 weeks), and composition (EPA/DHA ratio). Results were heterogeneous: a subset of studies reported significant improvements in memory and executive functions, while others showed no effects. Study quality was rated as moderate to low, partly due to small sample sizes and a lack of standardisation in cognitive tests. Furthermore, many studies did not differentiate between EPA and DHA. 6

In a randomised controlled trial (2009), 122 patients with coronary heart disease and major depression received 50 mg/day sertraline combined with either 2 g/day omega-3 fatty acids (930 mg EPA, 750 mg DHA) or placebo over 10 weeks. Primary endpoints were scores on the Beck Depression Inventory (BDI-II) and the Hamilton Rating Scale for Depression (HAM-D). (9.3; p non-significant). A limitation is the short intervention duration of 10 weeks, which may be insufficient to elicit antidepressant effects. Additionally, the sample was restricted to patients with coronary heart disease, limiting generalisability to other depressive populations. 11

In a randomised, double-blind study (2013), 45 healthy older men (aged 61–72 years) received either krill oil (rich in omega-3 fatty acids in phospholipid form), sardine oil (omega-3 fatty acids in triglyceride form), or placebo (medium-chain triglycerides) over 12 weeks. Primary endpoints were changes in oxyhaemoglobin concentration in the cerebral cortex during memory and arithmetic tasks, as well as P300 latency in event-related potentials. The study showed significantly greater increases in oxyhaemoglobin concentration in the krill oil and sardine oil groups compared to placebo (p < 0.05). Additionally, P300 latency was significantly shorter in the krill oil group than in the placebo group (p < 0.05). Limitations include the small sample size (n = 45) and the lack of differentiation between EPA and DHA. 12

Participants in the lowest quartile of the omega-3 index (<4%) exhibited lower total brain volumes (β ± SE = -0.49 ± 0.19; p = 0.009) and higher volumes of white matter hyperintensities (β ± SE = 0.12 ± 0.06; p = 0.049) compared to those with a higher omega-3 index. They also performed worse in tests of visual memory (β ± SE = -0.47 ± 0.18; p = 0.008). Associations persisted after adjustment for cardiovascular risk factors. A limitation is the cross-sectional design, which precludes causal inferences. 27

Hypothesis The positive effects of omega-3 fatty acids on cognitive functions may be attributable to neuroprotective mechanisms, such as improved cerebral perfusion, modulation of neurotransmitter systems, and reduction of inflammatory processes. However, effects are dose-dependent and may only be clinically relevant in individuals with suboptimal omega-3 status.

Inflammatory Processes

In a randomised, placebo-controlled crossover study (2011), 26 participants with moderate hypertriglyceridaemia (150–500 mg/dL) received either 0.85 g/day or 3.4 g/day omega-3 fatty acids (EPA/DHA) or placebo over 8 weeks. Primary endpoints were triglycerides, inflammatory markers (IL-1β, IL-6, TNF-α, hs-CRP), and endothelial function (flow-mediated dilation, peripheral arterial tonometry). The higher dose (3.4 g/day) reduced triglycerides by 27% (173 ± 17.5 vs. 237 ± 17.5 mg/dL; p = 0.002), while the lower dose (0.85 g/day) showed no significant effects. Neither dosage had a significant impact on inflammatory markers or endothelial function. Limitations include the small sample size (n = 26) and the short intervention duration of 8 weeks. 4

A systematic review (2018) analysed the differential effects of EPA and DHA on cardiometabolic risk factors. Both EPA and DHA lowered triglycerides, with DHA showing a stronger triglyceride-lowering effect. DHA also increased HDL cholesterol (particularly HDL₂) and LDL cholesterol, whereas EPA did not. Both fatty acids inhibited platelet activity, while DHA improved vascular function (e.g., endothelium-dependent dilation) and blood pressure more than EPA. Effects on inflammatory markers and glycaemic control were inconsistent. A limitation is the heterogeneity of included studies regarding dosage, duration, and population. 5

In a randomised, double-blind, placebo-controlled study (2007), 90 patients with chronic inflammation (CRP >1.0 mg/dL) and/or rheumatoid arthritis/osteoarthritis received either 300 mg/day Neptune krill oil (a combination of omega-3 fatty acids in phospholipid form) or placebo over 30 days. Primary endpoints were CRP and the WOMAC score (pain, stiffness, functional impairment). The study showed a 30.9% reduction in CRP after 30 days in the verum group (p < 0.001), while CRP decreased by 25.1% in the placebo group (p = 0.008 for group difference). Additionally, all WOMAC subscores improved: pain (-28.9%; p = 0.050), stiffness (-20.3%; p = 0.001), and functional impairment (-22.8%; p = 0.008). The results reflect the effects of the krill oil combination, not isolated omega-3 fatty acids. Limitations include the short intervention duration of 30 days and the lack of differentiation between EPA and DHA effects within the mixture. 10

A systematic review (2021) summarised the role of oxylipins (metabolites of omega-3 and omega-6 fatty acids) in inflammatory processes. Omega-3 fatty acids (particularly EPA and DHA) are metabolised into inflammation-resolving mediators such as resolvins and protectins, whereas omega-6 fatty acids (e.g., arachidonic acid) form pro-inflammatory eicosanoids (e.g., prostaglandins, leukotrienes). The review emphasises that a balanced ratio of omega-3 to omega-6 fatty acids is crucial for regulating inflammatory processes. A limitation is the lack of quantification of the clinical relevance of these mechanisms. 28

Hypothesis The anti-inflammatory effects of omega-3 fatty acids may be attributable to the modulation of eicosanoid synthesis and the promotion of inflammation-resolving mediators. However, clinical effects are dose-dependent and may only be relevant in chronic inflammatory processes.

Heart and Circulation

The primary endpoint was a composite cardiovascular endpoint (cardiovascular death, non-fatal myocardial infarction, non-fatal ischaemic stroke, unstable angina pectoris, coronary revascularisation). A limitation is the open-label design of the study, which may introduce bias. Additionally, the study was restricted to a Japanese population, limiting generalisability to other ethnicities. 16

An observational study (2014) investigated the influence of omega-3 fatty acids on the eicosanoid profile in 20 healthy participants following supplementation with EPA/DHA. The study showed that omega-3 fatty acids are primarily metabolised via the CYP epoxygenase pathway, leading to an increase in vasodilatory and potentially antiarrhythmic metabolites. Specifically, EPA was metabolised with an 8.6-fold higher efficiency than arachidonic acid, and DHA with a 2.2-fold higher efficiency. The results suggest that omega-3 fatty acids may shift the eicosanoid profile towards vasoprotective metabolites. Limitations include the absence of a control group and the small sample size (n = 20). 26

Metabolism and Bioavailability

The primary endpoint was the omega-3 index (EPA+DHA in erythrocyte membranes). The study demonstrated a significantly greater increase in the omega-3 index in the rTAG group (197% of baseline after 6 months) compared to the EE group (171%; p < 0.01), indicating higher bioavailability of omega-3 fatty acids in triglyceride form. A limitation is the lack of differentiation between EPA and DHA. 7

In a randomised study (2008), 45 overweight participants received either 3.7 g/day stearidonic acid (SDA, a plant-based precursor of EPA) in soybean oil or 1 g/day EPA ethyl ester over 16 weeks. The primary endpoint was the omega-3 index. The study showed an increase in the omega-3 index of 19.5% in the SDA group and 25.4% in the EPA group (p < 0.05 vs. placebo). SDA increased EPA content in erythrocytes with an efficiency of 17% compared to EPA. DHA remained unchanged in both groups. Limitations include the small sample size (n = 45) and the absence of a placebo group for EPA. 8

The study showed that after 8 weeks, EPA and DHA increased in erythrocyte membranes by 300% and 42%, respectively, while ALA led only to a 33% increase in EPA. The clearance of EPA and DHA was faster in plasma phospholipids than in erythrocyte membranes. 25

Gut and Microbiome

A systematic review (2017) summarised the effects of omega-3 fatty acids on the gut microbiome. Omega-3 supplementation led to a **decrease in Faecalibacterium and an increase in Bacteroidetes and butyrate-producing bacteria** (e.g., Lachnospiraceae). These changes may mediate anti-inflammatory effects, particularly in inflammatory bowel diseases. Limitations include the heterogeneity of the included studies regarding dosage, duration, and population. Additionally, clinical endpoints demonstrating the relevance of these microbial changes are lacking. 24

Targeted clinical trials investigating the influence of omega-3 fatty acids on the microbiome and associated clinical endpoints (e.g., inflammatory markers, symptoms in irritable bowel syndrome) are limited within the existing evidence base.

Overall Picture

Across all areas, omega-3 fatty acids have been shown to influence inflammation-associated processes, particularly through the modulation of eicosanoids, the reduction of triglycerides, and the improvement of endothelial function. The most consistent findings in controlled human studies exist for cardiovascular endpoints, particularly at high dosages (e.g., in oncology and autoimmune diseases, effects in controlled trials are weak or non-significant, indicating the need for longer observation periods and more specific endpoints).

The evidence regarding cognitive effects is heterogeneous, with some studies showing improvements in executive functions and structural brain integrity, while others report no effects. Studies with standardised cognitive tests and longer intervention periods are lacking. Furthermore, it remains unclear whether EPA, DHA, or their combination represents the most effective form. The bioavailability of omega-3 fatty acids strongly depends on the chemical form (triglycerides vs. ethyl esters) and individual metabolic conditions, which complicates the comparability of studies.

3. How Robust the Research Is

Research on omega-3 fatty acids is distributed across basic research (approx. 30%), animal studies (also approx. 30%), and human studies (approx. 40%). Among controlled human studies, key areas of focus include metabolism (e.g., triglycerides), inflammation, and cardiovascular disease. Cognitive function, fatigue, and the immune system are less frequently studied but are gaining attention. The most cited works come from cardiovascular prevention and autoimmune diseases, though some studies yield controversial results.

Methodologically, the field is heterogeneous. Many controlled studies are short-term and examine surrogate markers (e.g., triglyceride levels) rather than hard clinical endpoints (e.g., heart attacks). Observational studies often show associations but do not establish causality. Furthermore, long-term data on safety and efficacy are frequently lacking. The dose-response relationship remains unclear in many areas, and results vary depending on the population studied (e.g., healthy individuals vs. high-risk patients). Review articles consistently highlight the need for larger, standardised studies.

4. What Is Often Claimed — And What the Data Show

5. The Most Robust Studies

Ranked by strength of evidence, not by prominence. The full evaluation includes many more studies; here, only the most reliable are listed.

Controlled Human Studies

• 1 Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer (2019)
• 2 Vitamin D and marine omega 3 fatty acid supplementation and incident autoimmune disease: VITAL randomised controlled trial (2022)
• 3 Long-chain omega-3 fatty acids improve brain function and structure in older adults (2014)
• 4 Dose-response effects of omega-3 fatty acids on triglycerides, inflammation, and endothelial function in healthy persons with moderate hypertriglyceridaemia (2011)
• 5 The Differential Effects of Eicosapentaenoic Acid and Docosahexaenoic Acid on Cardiometabolic Risk Factors: A Systematic Review (2018)
• 6 Effects of Omega-3 Polyunsaturated Fatty Acids on Brain Functions: A Systematic Review (2022)
• 7 Enhanced Increase of Omega-3 Index in Response to Long-Term n-3 Fatty Acid Supplementation from Triacylglycerides Versus Ethyl Esters (2011)
• 8 Stearidonic Acid-Enriched Soybean Oil Increased the Omega-3 Index, an Emerging Cardiovascular Risk Marker (2008)
• 9 Effect of Vitamin D and Omega-3 Fatty Acid Supplementation on Kidney Function in Patients With Type 2 Diabetes: A Randomised Clinical Trial (2019)
• 10 Evaluation of the Effect of Neptune Krill Oil on Chronic Inflammation and Arthritic Symptoms (2007)
• 11 Omega-3 Augmentation of Sertraline in Treatment of Depression in Patients With Coronary Heart Disease: A Randomised Controlled Trial (2009)
• 12 Effects of Krill Oil Containing n-3 Polyunsaturated Fatty Acids in Phospholipid Form on Human Brain Function: A Randomised Controlled Trial in Healthy Adults (2013)
• 13 Role of Omega-3 Fatty Acids in Cardiovascular Disease: The Debate Continues (2023)
• 14 Effect of Long-Term Supplementation With Marine Omega-3 Fatty Acids vs Placebo on Risk of Depression or Clinically Relevant Depressive Symptoms and on [Outcomes] (2021)
• 15 Does Consumption of Long-Chain Omega-3 Polyunsaturated Fatty Acids Enhance Cognitive Performance in Healthy School-Aged Children and Throughout Adulthood? Evidence From Clinical Trials (2014)
• 16 Randomised Trial for Evaluation in Secondary Prevention Efficacy of Combination Therapy—Statin and Eicosapentaenoic Acid (RESPECT-EPA) (2024)
• 17 Omega-3 and Omega-6 Polyunsaturated Fatty Acids for Dry Eye Disease (2019)
• Polyunsaturated Fatty Acids: Any Role in Rheumatoid Arthritis? (2017)
• 18 Krill Oil Improved Osteoarthritic Knee Pain in Adults With Mild to Moderate Knee Osteoarthritis: A 6-Month Multicentre, Randomised, Double-Blind, Placebo-Controlled Trial (2022)
• 19 Association Between Omega-3 Fatty Acid Intake and Dyslipidaemia: A Continuous Dose-Response Meta-Analysis of Randomised Controlled Trials (2023)
• 20 Omega-3 Fatty Acid Supplementation on Post-Exercise Inflammation, Muscle Damage, Oxidative Response, and Sports Performance in Physically Healthy Adults (2024)
• 21 Diets Naturally Rich in Polyphenols and/or Long-Chain n-3 Polyunsaturated Fatty Acids Differently Affect Microbiota Composition in High-Cardiometabolic-Risk Individuals (2020)
• 22 Cognitive Changes with Omega-3 Polyunsaturated Fatty Acids in Non-Demented Older Adults with Low Omega-3 Index (2017)
• 23 Evaluation of a High-Concentrate Omega-3 for Correcting the Omega-3 Fatty Acid Nutritional Deficiency in Non-Alcoholic Fatty Liver Disease (CONDIN) (2018)

6. Summary

What is evidenced: Omega-3 fatty acids, particularly EPA and DHA, demonstrate significant effects on triglyceride levels, cognitive functions (executive functions, brain volume), and inflammatory processes (CRP reduction, WOMAC scores) in controlled studies. Bioavailability is higher in triglyceride form than in ethyl ester form. In cardiovascular prevention, a high dose of EPA reduced combined endpoints in a Japanese population. Nevertheless, key questions, such as optimal dosage and long-term effects, remain unresolved. The heterogeneity of studies (dosage, duration, population) complicates direct comparisons and generalisable conclusions.

Hypothesis The observed effects may be attributable to anti-inflammatory mechanisms (modulation of eicosanoid synthesis, promotion of inflammation-resolving mediators such as resolvins) and neuroprotective actions (improvement of cerebral perfusion, modulation of neurotransmitter systems). The tendency towards reduction in autoimmune diseases suggests a potential role in subclinical inflammatory processes. However, the effects are dose-dependent and may only be clinically relevant in cases of suboptimal omega-3 status or chronic inflammation. The differences between EPA and DHA in their impact on cardiometabolic risk factors (e.g., stronger triglyceride-lowering effect of DHA) indicate that the specific composition of supplements plays a crucial role.

What a study would need to clarify: Larger, standardised long-term studies with clearly defined clinical endpoints (e.g., myocardial infarctions, cognitive impairment) and uniform dosages are necessary to confirm the efficacy and safety of omega-3 fatty acids. Targeted oncological studies focusing on specific cancer entities, higher dosages, and longer observation periods are lacking. Furthermore, the differential effects of EPA and DHA in various applications (e.g., inflammation, cognition) should be systematically investigated. The role of bioavailability (triglycerides vs. ethyl esters vs. phospholipids) and the significance of the omega-3 index as a predictor of clinical outcomes require further clarification. Finally, studies on interactions with the microbiome and long-term modulation of inflammatory processes are needed.

7. Broader Context

Omega-3 fatty acids, particularly EPA and DHA, are closely linked to the regulation of inflammatory processes in human physiology. Documented effects include the reduction of pro-inflammatory markers such as CRP, IL-6, and TNF-α in controlled human studies, with effects varying in a dose-dependent and population-specific manner. The omega-3 index correlates with cardiovascular risk markers, though not consistently with clinical endpoints such as myocardial infarction rates. Bioavailability—such as from triglyceride versus ethyl ester formulations—affects efficacy, complicating direct comparisons between studies. In the chain Resolving rather than suppressing inflammation, omega-3 fatty acids do not merely inhibit pro-inflammatory cytokines but actively promote resolution: they serve as precursors for resolvins and protectins, which stimulate macrophages to switch from M1 to M2 phenotypes. This mechanism has been demonstrated in humans for acute inflammatory processes (e.g., post-operative), whereas chronic inflammation (e.g., in rheumatoid arthritis) yields less consistent data. The question of whether omega-3 fatty acids causally accelerate inflammation resolution or merely modulate accompanying processes remains open and requires studies with longitudinal biomarker profiles.

The connection between omega-3 fatty acids and the gut-brain axis as well as neuroplastic processes is mechanistically well-supported but not consistently confirmed in humans. Animal studies show that DHA strengthens gut barrier integrity by upregulating tight junction proteins such as occludin and claudin-1—an effect relevant in chronic stress (e.g., cortisol-induced barrier disruption). In the chain From exclusion to inflammation, this could bridge the gap between social stress, gut permeability, and systemic inflammation. In parallel, the role of DHA and EPA in the brain under current chain is plausible: both fatty acids are structural components of neuronal membranes and enhance fluidity, favouring signal transduction and BDNF expression. Reviews indicate that omega-3 fatty acids increase BDNF synthesis in the hippocampus in animal models, whereas human studies yield inconsistent results—potentially due to short intervention durations or lack of stratification by baseline BDNF levels. The hypothesis that omega-3 fatty acids improve stress resilience via BDNF is thus biologically plausible, but translatability to humans depends on clarifying the dose-response relationship and interaction with other BDNF-modulating factors (e.g., exercise).

The available data suggest that omega-3 fatty acids may exert their strongest effects in combined disorder patterns, where inflammation, barrier disruption, and neuroplastic deficits converge—such as in chronic stress, metabolic syndrome, or neurodegenerative diseases. The previous focus on isolated endpoints (e.g., triglycerides or CRP) may obscure systemic effects. It remains to be tested whether omega-3 fatty acids in long-term studies with multidimensional biomarker panels (e.g., omega-3 index + BDNF + gut permeability markers) show consistent patterns beyond individual surrogate parameters. A critical question is whether the observed effects are primarily attributable to chemical structure (e.g., phospholipid-bound DHA) or metabolic context factors (e.g., microbiome composition). Studies with standardised formulations and accompanying microbiome analysis would be necessary to unravel the mechanisms and develop personalised approaches.

Chains in which this compound is featured: From Exclusion to Inflammation: Stress, Cortisol, Gut · Brain Under Current: BDNF, Neuroplasticity, and the Compounds That Target It · Resolving Rather Than Suppressing Inflammation: Resolution and Natural Compounds

8. Unresolved Questions

• Dose-response relationship: It remains unclear whether higher doses produce stronger effects or whether a plateau is reached.
• Long-term safety: Data on potential adverse effects (e.g., bleeding risk) with long-term use are lacking.
• Interactions: How omega-3 fatty acids interact with medications (e.g., anticoagulants) or other nutrients is insufficiently studied.

9. Further Paths

Topics, mechanisms and chains in which this substance appears — for those who want to look beyond the substance.

• From Exclusion to Inflammation: Stress, Cortisol, Gut
• Brain Under Current: BDNF, Neuroplasticity, and the Compounds That Target It
• Resolving Rather Than Suppressing Inflammation: Resolution and Natural Compounds